Our study compared 84 patients with polycystic ovary syndrome (PCOS) with 84 control patients who had normal ovaries and who were matched for the main determinants of success in in-vitro fertilization (IVF) and embryo transfer. Serum concentrations of oestradiol and progesterone on the day of human chorionic gonadotrophin (HCG) injection were significantly higher in PCOS than in normal patients (oestradiol 2016 ⍨ 1.8 pg/ml versus 1456 ⍨ 40.9 pg/ml, P < 0.01; progesterone 1.6 ⍨ 0.1 ng/ml versus 1.2 ⍨ 0.1 ng/ml, P ⍧ 0.03). Furthermore despite oocytes from PCOS patients having a reduced fertilization rate compared with normal patients (61.8 ⍨ 4.1% versus 73.5 ⍨ 4.3%, P ⍧ 0.03), the differences in pregnancy rate (22.6 versus 19%) and miscarriage (31.5 versus 18.7%) were not statistically significant. In PCOS patients, a critical breakpoint was identified at serum progesterone concentrations of 1.2 ng/ ml on the day of HCG injection. The PCOS patients with progesterone ജ ജ1.2 ng/ml showed a higher pregnancy and miscarriage rate than PCOS patients with progesterone <1.2 ng/ml (26.6 versus 17.9%, P < 0.01; and 41.7% versus 14.3%, P < 0.01 respectively). These findings suggest that premature progesterone production does not have an adverse effect on pregnancy rate in PCOS, but on the contrary, may be a predictor for success in IVF/embryo transfer.
Introduction
Polycystic ovary syndrome (PCOS) is the endocrine disorder most frequently associated with anovulation and repeated spontaneous abortion (Erickson and Yen, 1993; Fedele and Bianchi, 1995) . For women with PCOS, failure to conceive can be treated with clomiphene citrate followed by treatment with gonadotrophins. In-vitro fertilization (IVF) and embryo transfer provide an additional line of treatment for PCOS patients who fail to conceive with follicle stimulating hormone (FSH) alone or in combination with gonadotrophin-releasing hormone agonist (GnRHa). There have been very few studies comparing the response of patients with or without PCOS to ovarian stimulation for IVF (Salat-Baroux et al., 1988; Dor et al., 1990; MacDougall et al., 1993; Homburg et al., 1993) . Several investigators have confirmed that a serum progesterone concentration Ͼ0.9 ng/ml on the day of human chorionic gonadotrophin (HCG) injection is associated with a reduced pregnancy rate in patients undergoing IVF (Silveberg et al., 1991; Schoolcraft et al., 1991; Mio et al., 1992; Kagawa et al., 1992; Franchin et al., 1993; Silveberg et al., 1994) . However, Hoffman et al. (1993 Hoffman et al. ( , 1996 observed no significant difference in pregnancy rate in patients undergoing IVF/embryo transfer with high or low progesterone concentrations on the day of HCG administration and in patients who received oocytes donated from women with high or low progesterone concentrations. Furthermore, Legro et al. (1993) demonstrated that premature luteinization as detected by elevated serum progesterone is associated with higher pregnancy rate in donor oocyte in IVF.
In the present study we retrospectively evaluated the outcome of IVF in patients with and without PCOS and the effect of an elevated progesterone concentration on the day of HCG administration on pregnancy rate.
Materials and methods

Patients
This retrospective study analysed the results of 84 patients with normal ovaries (control) and 84 patients with PCOS participating in an IVF programme in the University of Milan, San Raffaele Scientific Institute, Reproductive Endocrinology Center, OB/GYN Clinic, Italy. All patients had failed to conceive in four ovulatory cycles after ovulation induction with gonadotrophins. They had all been investigated by hysterosalpingography and some of them also by laparoscopy and hysteroscopy. All of the male partners had normal semen quality according to World Health Organization (WHO, 1992) criteria. A pure tubal factor was the cause of infertility in the control patients, whereas anovulation was the only cause for PCOS patients. PCOS were classified according to menstrual history, hirsutism, hormonal concentrations and ultrasound examination. PCOS was diagnosed on the basis of having the following criteria: a history of anovulatory infertility and/or oligomenorrhoea or amenorrhoea, a FerrimanGallwey score Ͼ7 for hirsutism, hyperandrogenaemia, elevated concentrations of luteinizing hormone (LH) or with a LH/FSH ratio of 2 or more, increased ovarian volume (Ͼ9 ml), and 10 or more follicles of 2-8 mm in diameter. Only two PCOS patients were considered to be overweight, although none was characteristically obese. Normal patients had a history of normal menstrual cycles, normal ovarian size and no more than five follicles Ͼ2 mm in diameter. 
Treatment protocol
All women in the IVF programme received a standard stimulation consisting of three ampoules per day of FSH (urofollitrophin, Metrodin; Serono, Rome, Italy) for 5 days. Adjustments of the dose of FSH were based on the individual dose response scheme whereby the dose was raised by one ampoule per day every 5 days until a follicular growth response and an increase in oestradiol concentration were noted. Final maturation of the oocytes was effected with 5000 IU HCG (Profasi; Serono, Rome, Italy) when there were at least two follicles Ͼ16 mm. Ovum retrieval was performed 32-36 h after HCG administration by vaginal ultrasound and embryo transfer 48 h later. The GnRHa employed was buserelin (Suprefact; Hoechst, L'Aquila, Italy) at a dose of 200 µg three times/day via intranasal spray. In women with PCOS, GnRHa was administered 3 weeks after a progestin-induced withdrawal bleed or spontaneous menstruation. In the control group, GnRHa was administered on days 20-21 of the cycle. At 2 weeks after GnRHa the serum concentration of oestradiol was measured and ultrasound examination of the ovaries performed. If the oestradiol concentration was Ͻ50 pg/ml and there were no follicles or cysts Ͼ10 mm diameter, gonadotrophin treatment was started. If this ovarian quiescence had not been achieved, a further examination was performed 1 week later.
Statistical analysis
All results are reported as the mean Ϯ SE. Differences in the mean values for individual hormone measurements were assessed by using analysis of variance and two-tailed group t-test. Serum progesterone breakpoints were optimized by summing the true positive rate and the true negative rate for each potential progesterone thresold from 0-1.8 ng/ml in increments of 0.1 ng/ml. This method is a variation of receiver operating characteristic (ROC) curve analysis (Hanely and McNeil, 1982) . P Ͻ 0.05 was considered to be statistically significant.
Results
There were no significant differences in age and FSH of the patients with PCOS compared with those with normal ovaries (Table I) . Body mass index (BMI), LH and androgen (testosterone and androstenedione) concentrations were, as expected, significantly raised (P ϭ 0.04 and P Ͻ 0.01 respectively) in the PCOS patients compared with those in the controls (Table I) . Despite receiving significantly fewer ampoules of follicle stimulating hormone FSH (P ϭ 0.02) with fewer days of stimulation (P ϭ 0.03), peak serum oestradiol concentrations were significantly higher (P Ͻ 0.01) in the PCOS group compared with the controls (Table II) . Serum concentrations of progesterone on the day of HCG injection (35 h before follicular aspiration) were significantly higher (P ϭ 0.03) in PCOS than in control patients (Table II) . Furthermore, patients with PCOS developed significantly more follicles on the day of HCG administration (P Ͻ 0.01) compared with patients with normal ovaries irrespective of the size of the follicles and more oocytes were collected in the patients with PCOS (Table II) . The mean fertilization rate in the patients with PCOS was 61.8 Ϯ 4.1 compared with 73.5 Ϯ 4.3 in the controls and this difference was statistically significant (P ϭ 0.03) ( Table II) . The mean number of embryos transferred in both groups was similar (2.3 Ϯ 0.4 and 2.3 Ϯ 0.3) (Table II) .
There was a total of 19 (22.6%) pregnancies in the PCOS patients compared with 16 (19%) in the control group. Of these, six (31.5%) miscarried in the PCOS group compared with three (18.7%) in the control group. This difference was not significant (Table II) . No patients in either group developed severe ovarian hyperstimulation syndrome following their IVF cycle. In PCOS patients a critical breakpoint of 1.2 ng/ml was identified in serum progesterone concentrations on the day of Figure 1 . The effects of different threshold values of progesterone on the predictive value of pregnancy in patients with polycystic ovary syndrome (PCOS). The true positive rate (achieving a pregnancy if below the threshold) and the true negative rate (not achieving a pregnancy if above the threshold) were summed for each potential threshold value from 0-1.8 ng/ml in increments of 0.1 ng/ml. HCG administration (Figure 1 ). PCOS patients were thus divided into two groups according their progesterone concentrations: Ͻ1.2 ng/ml and ജ1.2 ng/ml (Table III) . The PCOS patients with progesterone ജ1.2 ng/ml (n ϭ 45) had significantly higher serum oestradiol on the day of HCG administration with higher pregnancy rate and more miscarriages than did those with progesterone Ͻ1.2 ng/ml (n ϭ 39). The differences of total number of FSH ampoules, day of HCG administration, number of oocytes obtained, fertilization rate and number of embryos transferred were not statistically significant between the two groups. In the control group the number of oocytes obtained was higher in patients with progesterone ജ1.2 ng/ml than in those with progesterone Ͻ1.2 ng/ml and this was the only statistically significant difference (Table IV) .
Discussion
In the present study we have compared patients with PCOS and control patients who had normal ovaries and who matched for the main determinants of success in IVF. We found that: (i) despite a reduced fertilization rate in oocytes from PCOS patients compared with normal patients, the difference in pregnancy rate and and miscarriage were not statistically significant; (ii) serum concentrations of oestradiol and progesterone on the day of HCG injection are significantly higher in PCOS patients; and (iii) using ROC analysis in PCOS patients, a critical breakpoint on the day of HCG injection was identified at progesterone concentration of 1.2 ng/ml and PCOS patients with progesterone ജ1.2 ng/ml showed a higher pregnancy rate.
The response of patients with PCOS to ovulation induction is different from normal subjects (Hamilton-Fairley and Franks, 1990) . Patients with PCOS have a greater number of follicles and oocytes, and reduced fertilization rate compared with patients with normal ovaries, but no difference in pregnancy rate and miscarriage (Dor et al., 1990; MacDougall et al., 1993) . In agreement with these studies we found significantly higher peak serum oestradiol concentrations, number of follicles on the day of HCG injection, and number of oocytes collected. Oocytes from PCOS patients have reduced fertilization rate due to increased number of small and medium sized follicles. It is generally recognized that oocytes from relatively immature follicles have a lower fertilization rate compared with those from pre-ovulatory follicles.
Furthermore, in our study we confirmed that there is not a statistically significant difference in pregnancy rate and miscarriage. In a previous study that has been done on a smaller number of patients, we showed that serum progesterone on the day of HCG administration is significantly higher in PCOS compared with normal patients that undergo IVF cycles (Doldi et al., 1998) . The significance of elevated progesterone concentrations at the time of HCG administration is not clearly known and opinion is somewhat divided. Several investigators have confirmed that high progesterone is associated with decreased success in IVF/embryo transfer cycles (Schoolcraft et al., 1991; Silveberg et al., 1991; Mio et al., 1992; Kagawa et al., 1992; Franchin et al., 1993; Silveberg et al., 1994) . It has been suggested that this might be due to marked elevations in serum LH concentrations associated with elevated serum progesterone concentrations, rather than to premature progesterone production (Kagawa et al., 1992) . Studies by Harada et al. (1995 Harada et al. ( , 1996 showed that a rise in progesterone occurs even in patients with a combination of GnRH analogue and human menopausal gonadotrophin (HMG) without concomitant significant increase in immunoreactive LH and bioactive LH. These results, together with others (Silveberg et al., 1991; Schoolcraft et al., 1991) , suggest that an endogenous LH rise may not be associated with these progesterone rises. It is more likely that luteinization occurred because of the excessive sensitivity of granulosa cells, rather than in response to excessive LH stimulation. Furthermore, Silveberg et al. (1991) observed a significantly greater fertilization rate in oocytes obtained from cycles in which progesterone concentration was Ͼ0.9 ng/ml compared with oocytes obtained from low progesterone cycles.
Therefore, it appears that premature progesterone production does not exert its adverse effect at the level of the oocyte. On the other hand Hoffman et al. (1996) observed no significant difference in pregnancy rate in patients undergoing IVF/embryo transfer cycles with high or low progesterone concentrations on the day of HCG injection. Furthermore, Legro et al. (1993) demonstrated that premature luteinization as detected by elev-604 ated serum progesterone is associated with high pregnancy rate with donor oocytes in IVF. In our study the difference in progesterone production between normal and PCOS patients on the day of HCG administration had no impact on pregnancy rate and miscarriage. Using a breakpoint of serum progesterone level of 0.9 ng/ml on the day of HCG injection (data not shown) as suggested by numerous published reports (Schoolcraft et al., 1991; Mio et al., 1992; Kagawa et al., 1992; Franchin et al., 1993) , we found that PCOS patients with progesterone ജ0.9 ng/ml showed a higher pregnancy rate. Using ROC analysis a critical breakpoint was identified at progesterone level of 1.2 ng/ml that is associated with pregnancy outcome. PCOS patients with progesterone ജ1.2 ng/ml showed a higher pregnancy rate. Silveberg et al. (1994) observed that embryos obtained from IVF cycles in which premature progesterone production occurred, resulted in pregnancy at least as often as did embryos obtained from IVF in which premature progesterone production did not occur, with a trend toward a higher pregnancy rate with premature progesterone production.
Furthermore, previous studies, including our study, demonstrated that in-vivo and in-vitro progesterone production of PCOS granulosa cells is abnormal (Erickson et al., 1992; Doldi et al., 1998) . Gilling-Smith et al. (1994) showed that in theca cells of PCOS ovaries, the androstenedione to progesterone ratio is significantly higher suggesting increased conversion of progesterone to androstenedione. Based on this information and on our results it seems that premature progesterone production does not have an adverse effect on pregnancy rate in PCOS, but on the contrary, may be a predictor for success in IVF/embryo transfer.
